Fig. 6
Anti-tumor effects of NK101 and NK-92 in immunocompetent 4T1 tumor model. a Experiment schema: Balb/c mice were injected with 1 × 106 cells of 4T1 expressing EGFP-fLuc cells subcutaneously. After palpable tumors had formed, the mice were grouped based on tumor size. 5 × 106 cells of NK-92 or NK101 were injected peritumorally for 4 times at days 7, 10, 13 and 16. Tumor size was monitored for 3 weeks (b) and bioluminescent imaging was performed on day 21 (c). b The change of tumor size in the individual mice over time was represented by a line. c Bioluminescent signals were quantitated using Amiview and plotted as bar graph. Data represent mean ± SD of 5 mice per group from 2 independent experiments (left). Representative tumor images in each group are also shown (right). d Kaplan-Meier survival curve of 4T1-bearing mice treated by serum-free media, NK-92 or NK101 is shown (n = 5, representative of 2 independent experiments). e Splenocytes from tumor-bearing mice treated with serum-free media, NK-92, or NK101 were prepared for IFN-γ ELISPOT assay. Cells were stimulated by 50 μg/ml of tumor lysates for 24 h. The frequency of IFN-γ+ spot forming cells (SFCs) per 106 splenocytes is displayed. Data represent mean ± SD of triplicate wells from 2 independent experiments. *p < 0.05, **p < 0.01